Daily Cardiology Research Analysis
Analyzed 228 papers and selected 3 impactful papers.
Summary
Three impactful cardiology studies stood out today: a massive target-trial emulation supports lower blood pressure targets (<130/80 mmHg) in adults ≥60 years without increased adverse events; a cardiovascular MRI study identifies a reproducible, field-strength–dependent blood-pool T2 biomarker (RV/LV T2 ratio) that independently predicts major adverse cardiac events; and a randomized trial analysis shows mavacamten significantly improves patient-reported symptoms in obstructive hypertrophic cardiomyopathy. Together, these findings inform guideline targets, refine noninvasive risk stratification, and validate symptom relief with a novel therapy.
Research Themes
- Blood pressure targets in older adults
- CMR-derived prognostic biomarkers
- Patient-reported outcomes with novel HCM therapy
Selected Articles
1. Impact of Mavacamten on Disease-Related Symptoms in Patients With Obstructive Hypertrophic Cardiomyopathy: HCMSQ Outcomes in EXPLORER-HCM.
In EXPLORER-HCM, mavacamten produced significantly greater improvements than placebo across HCMSQ domains (shortness of breath, tiredness, and cardiovascular symptoms) and in total score over 30 weeks, with higher responder rates. Symptom gains reversed upon treatment cessation, and dyspnea scores correlated with E/e′ and LVOT gradients, linking PROs to physiological measures.
Impact: Provides robust patient-centered evidence that mavacamten improves symptom burden in obstructive HCM, complementing physiologic benefits and supporting value-based adoption. PRO–physiology correlations strengthen interpretability for clinical practice.
Clinical Implications: For symptomatic obstructive HCM, mavacamten can meaningfully reduce dyspnea, fatigue, and cardiovascular symptom burden as captured by the HCMSQ; PRO monitoring may guide titration and shared decision-making. Symptom reversal after withdrawal underscores the need for sustained therapy to maintain benefit.
Key Findings
- Mavacamten significantly improved HCMSQ shortness of breath, tiredness, cardiovascular symptoms, and total scores vs placebo at 30 weeks (all P<0.001).
- Responder rates were higher with mavacamten across HCMSQ domains (e.g., SoB 52.9% vs 18.6%).
- Benefits reversed after treatment withdrawal, and SoB scores correlated with E/e′ and LVOT gradients.
Methodological Strengths
- Phase 3, double-blind, randomized controlled design with prespecified PRO assessment.
- Use of a disease-specific, validated PRO instrument (HCMSQ) and responder analyses.
Limitations
- PRO completion less than the full randomized cohort at week 30 may introduce response bias.
- Duration limited to 30 weeks; long-term durability and real-world adherence not addressed.
Future Directions: Evaluate long-term PRO durability, dose–response strategies linked to symptom targets, and integration of PROs into routine care pathways and payer value frameworks.
BACKGROUND: The Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ) is the first patient-reported outcome tool to measure cardinal symptoms of HCM. We examined the impact of mavacamten on HCM symptoms measured by the HCMSQ. METHODS AND RESULTS: EXPLORER-HCM (NCT03470545) was a phase 3, double-blind, randomized trial in 251 adults with symptomatic obstructive HCM who received mavacamten or placebo for 30 weeks. Changes in the HCMSQ shortness of breath (SoB), the tiredness, the cardiovascular symptoms domains and total scores were assessed. Responder analyses, impact of withdrawing treatment, and associations between HCMSQ scores and echocardiographic parameters were explored. A total of 217 patients completed the HCMSQ at baseline (mavacamten, n = 108; placebo, n = 109), and 171 patients completed it at week 30 (mavacamten, n = 85; placebo, n = 86). At week 30, patients receiving mavacamten experienced significantly greater improvements from baseline in HCMSQ SoB, tiredness, and cardiovascular symptoms domains and total score versus placebo (all P<0.001). Higher proportions of patients receiving mavacamten versus placebo experienced meaningful improvements in HCMSQ SoB domain (52.9% vs 18.6%), tiredness domain (23.5% vs 12.8%), cardiovascular symptoms domain (42.4% vs 22.1%), and total (36.5% vs 14.0%) scores. Therapy cessation was associated with return to baseline in HCMSQ scores by week 38. HCMSQ SoB domain score was significantly associated with echocardiographic E/e' lateral and resting and Valsalva left ventricular outflow tract gradient. CONCLUSIONS: In patients with obstructive HCM, mavacamten markedly reduced patient-reported symptom burden measured by the HCMSQ compared with placebo. REGISTRATION: URL: https://clinicaltrials.gov/study/NCT03470545. Unique identifier: NCT03470545.
2. Field Strength Dependence, Physiologic Correlates, and Prognostic Significance of Ventricular Blood Pool T2 Mapping on Cardiovascular Magnetic Resonance Imaging.
In 718 individuals, the RV/LV blood-pool T2 ratio was highly reproducible, field-strength dependent (higher at 1.5T than 3T), and independently predicted MACE; optimal cut-points were <0.70 (1.5T) and <0.55 (3T). Lower ratios correlated with reduced peak VO2 on CPET, linking this imaging biomarker to functional capacity; absolute RV blood-pool T2 had similar prognostic value.
Impact: Establishes a practical, noncontrast CMR biomarker that ties myocardial oxygenation physiology to outcomes with field-specific thresholds, enabling refined risk stratification and standardization across 1.5T and 3T scanners.
Clinical Implications: CMR services can incorporate RV/LV blood-pool T2 ratio (and/or absolute RV T2) with field-specific cutoffs to identify higher-risk patients and align with exercise capacity. Reporting should specify magnet strength and thresholds to avoid misclassification.
Key Findings
- RV/LV blood-pool T2 ratios were 18–31% higher at 1.5T vs 3T and showed excellent reproducibility (ICC ≥0.95).
- Each 0.1-unit decrease in RV/LV T2 ratio independently increased MACE hazard by ~41–42% with field-specific cut-points (<0.70 at 1.5T, <0.55 at 3T).
- Lower RV/LV T2 ratios correlated with reduced percent-predicted VO2 on CPET; absolute RV T2 had comparable prognostic performance.
Methodological Strengths
- Large cohort with both 1.5T and 3T scanners and healthy controls; high reproducibility (inter/intra-observer ICC).
- Multivariable prognostic modeling with field-specific ROC analyses and physiologic validation via CPET.
Limitations
- Retrospective design with potential selection bias; external validation not yet reported.
- CPET data were available in a subset (n=150), which may limit generalizability of physiologic correlations.
Future Directions: Prospective, multicenter validation; integration into standardized CMR reporting; evaluation of therapy responsiveness and incremental value over established markers.
BACKGROUND AND PURPOSE: CMR T2 mapping is sensitive to blood oxygenation. The purpose was to evaluate determinants of the right-to-left ventricular (RV/LV) blood pool (BP) T2 ratio, determine field strength-specific cut-points for prediction of major adverse cardiac events (MACE), and assess physiologic correlates. METHODS: Adults undergoing CMR (at 1.5T or 3T) for evaluation of cardiomyopathy between 2018 and 2020 were retrospectively evaluated along with healthy controls. RV and LV BP T2 values were measured on a mid-ventricular short-axis T2 map with calculation of the RV/LV BP T2 ratio. Reproducibility was assessed in a random subset of 100 patients. Associations with cardiopulmonary exercise testing (CPET) parameters and major adverse cardiac events (MACE) were evaluated using Spearman correlation, Cox regression, and receiver operating characteristic analysis. RESULTS: A total of 718 subjects were included: 678 with cardiomyopathy (mean age 50±16 years; 58% men) and 40 controls (mean age 45±15 years; 55% men). Over a median follow-up of 3.2 years (IQR 2.3-3.8), 53 patients experienced MACE. RV/LV BP T2 ratios were 18-31% higher at 1.5T versus 3T (cardiomyopathy: 0.77±0.14 vs 0.59±0.13, p<0.001; controls: 0.79±0.11 vs 0.67±0.09, p<0.001) with excellent reproducibility (intra-observer ICC 0.96 and inter-observer ICC 0.95). Each 0.1-unit decrease in RV/LV BP T2 ratio was associated with 41-42% increased hazard of MACE in multivariable analysis (HR 0.59, 95%CI 0.45, 0.78, p<0.001 at 1.5T and HR 0.58, 95%CI 0.40, 0.85, p=0.005 at 3T). Optimal cut-points for prediction of MACE were <0.70 at 1.5T (AUC 0.727) and <0.55 at 3T (AUC 0.689). Absolute RV BP T2 demonstrated similar prognostic performance. Among patients with CPET (n=150), lower RV/LV BP T2 ratios correlated significantly with reduced percent-predicted oxygen uptake (VO CONCLUSIONS: The RV/LV BP T2 ratio reflects clinically meaningful cardiopulmonary physiology and independently predicts MACE, but is strongly influenced by MRI field strength, challenging assumptions of inherent field-independence and necessitating field strength-specific thresholds. Absolute RV BP T2 demonstrated comparable prognostic performance and may serve as a practical complementary metric. These findings establish RV BP T2 metrics as promising biomarkers for improved risk stratification in clinical CMR.
3. The optimal blood pressure target in old and very old patients with hypertension.
In a target-trial emulation of 132,430 adults ≥60 years with hypertension, a lower BP target (<130/80 mmHg) was associated with reduced cardiovascular events and all-cause mortality across 60–69, 70–79, and ≥80-year groups, without increasing major adverse events. Benefits were consistent in subgroup analyses, supporting stricter targets in older adults.
Impact: Provides large-scale, real-world evidence across older age strata that tighter BP control improves outcomes without excess harm, informing guideline debates for the elderly and very elderly.
Clinical Implications: Clinicians may consider aiming for <130/80 mmHg in adults ≥60 years when feasible, balancing comorbidities and preferences; careful monitoring remains essential though major adverse events did not increase in this study.
Key Findings
- Lower BP target (<130/80 mmHg) reduced major CVD and all-cause mortality across 60–69, 70–79, and ≥80-year groups (e.g., ≥80 years CVD HR 0.77).
- No significant increase in major adverse events related to antihypertensive treatment was observed in any age group.
- Results were consistent across prespecified subgroups, supporting robustness.
Methodological Strengths
- Very large sample with target trial emulation to mitigate confounding by indication.
- Stratification by age (including ≥80 years) and comprehensive outcome assessment.
Limitations
- Observational design with residual confounding possible despite emulation.
- BP target assignment and adherence not randomized; measurement variability in EMR data.
Future Directions: Prospective pragmatic trials in very old adults, evaluation of frailty/cognition trade-offs, and implementation studies on achieving <130/80 mmHg safely in multimorbidity.
BACKGROUND: With the rise in older population globally, the optimal blood pressure (BP) target for antihypertensive therapy in those aged 60 and above remains to be evaluated in the real-world practice. This study evaluated the effectiveness and safety of standard versus lower BP targets in old (aged 60-79) and very old (aged ≥80) patients with hypertension in real-world clinical settings. METHODS: We emulated a target trial using electronic medical records from the Hong Kong Hospital Authority, including patients aged 60 years or above with a diagnosis of hypertension, uncontrolled BP and records of antihypertensives adjustments from 2008 to 2013. Patients were first categorized into 3 age groups (60-69, 70-79, ≥ 80) and then assigned to BP targets of either 130-140/80-90 mmHg or below 130/80 mmHg. Outcomes included major cardiovascular disease (CVD), end-stage renal disease, all-cause mortality and major adverse events related to antihypertensive treatment. RESULTS: Of 132 430 eligible patients identified, 52 553, 28 661 and 7106 patients aged 60-69, 70-79 and ≥ 80 years had BP targets of 130-140/80-90 mmHg, respectively; 11 148, 5636 and 1203 of patients in the same age groups had targets below 130/80 mmHg. Lower BP target was associated with reduced overall CVD and all-cause mortality: aged 60-69 years (CVD HR: 0.91 [95% CI, 0.85-0.96]; all-cause mortality: 0.89 [0.81-0.98]), aged 70-79 years (CVD: 0.87 [0.82-0.93]; all-cause mortality: 0.84 [0.78-0.91]), and aged≥80 years (CVD: 0.77 [0.69-0.86]; all-cause mortality: 0.80 [0.72-0.89]). No significant increase in major adverse events was observed in any age group. Results were consistent across all subgroups. CONCLUSION: Lowering BP of below 130/80 mmHg in old and very old patients was associated with better cardiovascular and mortality outcomes without increased adverse events. These findings suggest that a lower BP target may be beneficial and safe for older patients with hypertension.